TO Tim Opler Tim Opler Managing Director in Stifel's Global Healthcare Group who advises biotech and pharma companies on M&A, licensing and financings.

“Historically, if a rumor appears that company X has interest from company Y, there's a 14% chance that transaction actually happens. If it appears in the Wall Street Journal, there's a two in three chance. 50% if it's in the Financial Times. If it's in Bloomberg, it's a 37% chance.”

Biotech Hangout · Health & Longevity · November 2026

“Historically, if a rumor appears that company X has interest from company Y, there's a 14% chance that transaction actually happens. If it appears in the Wall Street Journal, there's a two in three chance. 50% if it's in the Financial Times. If it's in Bloomberg, it's a 37% chance.” — Tim Opler, Biotech Hangout

Context

The group was discussing a Bloomberg report that Sanofi was weighing a bid for Insmed. Opler cites his own study of about a hundred M&A rumors from recent years to explain why he's skeptical of this one.

Transcript

Biotech Hangout Around 25:32 into the episode
Tim Opler

on that?

Matt Gline

Sure.

Tim Opler

On Instmed. So back in February, I published a little piece called Cheat Talk: Fake News and Biotech M ⁇ A Rumors. And I looked at 103 rumors that had appeared in the news between June 2021 and January 2026. So if a rumor appears that says XYZ company has interest from ABC company, historically, there's a 14% chance that that transaction actually happens. And if the rumor appears, any rumor appears about an MA in the Wall Street Journal, there's a two in three chance that it will happen. 50% chance if it's in the Financial Times. And if it's in Bloomberg, it's a 37% chance. So this is just looking at the rumor itself, a particularly weak rumor, because it says that Sanofi is considering buying Instmed. And it appeared in Bloomberg, which has a record of, let's just say, probably a lower threshold of publishing rumors. So I'm a skeptic on this one. I would also note that Paul Hudson is on the board of InSMED. And while Will Lewis was indeed a former CIA officer, one of my friends saw him just a week ago, and he looked incredibly relaxed and happy. Not a guy that…

Graig Suvannavejh

I'll leave it to Tim to do that analysis, which is incredible. Thank you for those statistics. Yeah, we will see what transpires here. We published a note this week since, again, I cover InSMED. I didn't think that this deal was going to go down at least immediately, but I do think that given the…

Tim Opler

Yeah, well, I mean, look, it's notable that they mentioned the upfront, which I think we want to see more of. But yeah, first, I think the industry should, you know, pitch in and buy a big collective effort to get a Christmas present to Lilly this year because they really, I think I read that there…

Graig Suvannavejh

biparotropic double-barreled antibody for the treatment of myeloproliferative neoplasms. These are rare blood cancers like myelofibrosis, thrombocythemia. These are currently treated with blood transfusions or Insights Jack inhibitor. Lilly also has other programs in these spaces. So they're…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout